IP Library Granted Patent US 8,765,469
Granted Patent B2
US 8,765,469 · App. 11/990,443 · Granted Jul 1, 2014

Method of producing lymphocytes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,469
App. No.
11/990,443
Granted
Jul 1, 2014
Kind
B2
Abstract

A method for preparing lymphocytes characterized in that the method comprises the step of carrying out expansion in the presence of (a) fibronectin, a fragment thereof or a mixture thereof, (b) a CD3 ligand, and (c) a CD28 ligand.

Claims (14)

1. A method for preparing lymphocytes suitable for adoptive immunotherapy comprising the step of carrying out expansion in the simultaneous presence of (a) fibronectin, a fragment thereof or a mixture thereof, (b) an immobilized CD3 ligand, and (c) an immobilized CD28 ligand.

2. The method according to claim 1 , wherein the CD3 ligand is an anti-CD3 antibody.

3. The method according to claim 1 , wherein the CD28 ligand is an anti-CD28 antibody.

4. The method according to claim 1 , wherein the fibronectin fragment is a polypeptide (m) comprising at least any one of the amino acid sequences shown in SEQ ID NOs: 1 to 8 of Sequence Listing, or a polypeptide (n) comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or plural number of amino acids in any one of said amino acid sequences, wherein the polypeptide (n) has a function equivalent to said polypeptide (m).

5. The method according to claim 4 , wherein the fibronectin fragment has a cell adhesion activity and/or a heparin binding activity.

6. The method according to claim 5 , wherein the fibronectin fragment is at least one polypeptide selected from the group consisting of polypeptides having any one of the amino acid sequences shown in SEQ ID NOs: 9 to 21 of Sequence Listing.

7. The method according to claim 1 , wherein the lymphocytes are lymphokine-activated cells.

8. The method according to claim 1 , further comprising the step of transducing a foreign gene into lymphocytes.

9. The method according to claim 8 , wherein the foreign gene is transduced using retrovirus, adenovirus, adeno-associated virus, lentivirus or simian virus.

10. A method for preparing a solid phase comprising:

contacting the solid phase with (a) fibronectin, a fragment thereof or a mixture thereof, (b) a CD3 ligand and (c) a CD28 ligand under an acidic condition.

11. The method according to claim 10 , wherein the solid phase is a cell culture carrier.

12. A solid phase to which (a) fibronectin, a fragment thereof or a mixture thereof, (b) a CD3 ligand, and (c) a CD28 ligand are immobilized.

13. The solid phase according to claim 12 , wherein the solid phase is a cell culture plate, a petri dish, a flask, a bag, beads, a membrane or a slide glass.

Assignments (2)
CHANGE OF ADDRESS Recorded Jun 24, 2016
From: TAKARA BIO INC.
To: TAKARA BIO INC.
Reel/Frame 039152/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2008
From: MARUI, TAKAHIRO; NAGAMINE, KINUKO; MURAKI, NOBUKO; KATO, AKIKO; ENOKI, TATSUJI; SAGAWA, HIROAKI; KATO, IKUNOSHIN
To: TAKARA BIO INC.
Reel/Frame 020565/0926 →